Short Reads

Dissemination of misleading information on the safety of a medical product can be a "by object" infringement

Dissemination of misleading information on the safety of a medical pr

Dissemination of misleading information on the safety of a medical product can be a "by object" infringement

01.02.2018 NL law

On 23 January 2018, the European Court of Justice delivered its judgment on a request for a preliminary ruling by the Italian Council of State. The request concerned an agreement between Roche and Novartis to make public statements concerning the alleged lack of safety and efficacy of one of Roche's products which competed with a product licensed to Novartis (the Agreement). The Court of Justice found that such an agreement can, under specific circumstances, constitute a restriction of competition "by object".

Genentech, a subsidiary of Roche, developed bevacizumab (Avastin) and ranibizumab (Lucentis). Avastin was developed to treat certain types of cancer. Lucentis was specifically developed to treat ocular diseases. Genentech licensed Avastin to its parent Roche and, since Roche was not active in the ophthalmological field, it licensed Lucentis to Novartis.

Prior to the market launch of Lucentis in Italy, doctors started prescribing the oncological drug Avastin as a treatment for eye diseases, despite the fact that such use was not included in Avastin's marketing authorisation (off-label use). Given its lower price, the off-label use of Avastin continued well after the market launch of Lucentis.

The Italian Competition Authority (ICA) had found that, following the market launch of Lucentis, Roche and Novartis (the Parties) entered into an agreement with the aim to artificially differentiate between Avastin and Lucentis by exaggerating the risks associated with the off-label use of Avastin while claiming that Lucentis had a better safety profile. According to the ICA, these statements were made without sufficient scientific evidence. The Parties intended to use this Agreement to prevent the further expansion of Aventis in the ophthalmological field and to promote Lucentis instead. According to the ICA, the Agreement intended to unlawfully maximise the profits of the Parties by promoting the most expensive product, namely Lucentis. Consequently, the ICA found that the Parties had entered into a market-sharing agreement, which constitutes a restriction of competition "by object".

The Parties challenged the decision of the ICA before the Italian Council of State, which referred the case for a preliminary ruling to the Court of Justice. The key issue before the Court of Justice was whether an arrangement between competing undertakings to disseminate unconfirmed scientific information on the off-label use of one of their products, with the aim or reducing the competitive pressure exerted on the other product, could constitute a restriction of competition "by object".

The Court first established that medicines that have a marketing authorisation (MA) for a specific indication and medicines used off-label for the same indication can, under circumstances, actually compete in same relevant market.

Next, the Court found, siding with the Advocate General's opinion, that the Agreement could indeed be considered a "by object" restriction of competition. First, the Court emphasized that the responsibility to report any potential adverse effects to the authorities and consequently to professionals and the general public lies with the MA holder alone and not with another company marketing a competing product under a separate MA. In this case, it was not only the MA holder, i.e. Roche, that had been involved in the relevant communications but also Novartis. According to the Court, this provides an indication that the communications may not have been solely driven by objectives related to pharmacovigilance. 

Secondly, the Court found that if the information shared by the Parties was misleading, then the Agreement should be considered a "by object" infringement. The Court held that such information should be considered as misleading if– in short – it was shared with the purpose of confusing the relevant authorities on the safety profile of Avastin so they would include in its summary of characteristics the alleged adverse reactions, which would then allow Roche to launch a communication campaign in which the safety risks could be exaggerated vis-à-vis doctors and the general public. The Court left this assessment to the Italian Court.

This case is important as it effectively marks the introduction of the doctrine of disparagement in EU competition law. Similar cases (see Sanofi-Aventis decision) have been pursued in France where the competition authority found – and courts have confirmed – that the dissemination of misleading information about a pharmaceutical product's characteristics can infringe competition rules.

This article was published in the Competition Law Newsletter of January 2018. Other articles in this newsletter:

  1. Qualifying dawn raid documents as 'in scope' or 'out of scope': marginal review by Belgian Court
  2. Highest German Court rules that ASICS's ban on using price comparison websites violates EU competition law

Team

Related news

18.02.2019 BE law
Plan-MER voor Vlaams windturbinekader? Raad voor Vergunningsbetwistingen te rade bij Europa

Articles - Het wordt stilaan een traditie van de Belgische rechter om het Hof van Justitie te bevragen over de milieueffectenbeoordeling en -rapportage (MER). Na de Raad van State en het Grondwettelijk Hof is het de beurt aan de Raad voor Vergunningsbetwistingen. In een tussenarrest van 4 december 2018 heeft de Raad voor Vergunningsbetwistingen aan het Hof van Justitie een lijst met prejudiciële vragen gesteld over de plan-MER-plicht van het Vlaamse kader voor de uitbating van windturbines. Mogen we ons verwachten aan een juridische saga "d'Oultremont pt.II"?

Read more

07.02.2019 NL law
Follow-on cartel damages claim dismissed: don't bury courts under paper work

Short Reads - A recent ruling by the Dutch Court of Appeal confirmed that claimants will need to sufficiently substantiate their claim that they suffered loss due to a cartel, even in follow-on cases. Despite a presumption that sales or service contracts concluded during the cartel period have been affected by the cartel, claimants will still need to provide the courts with concrete, detailed and uncluttered information showing (i) which party purchased (ii) which products from (iii) which manufacturer for (iv) which amount, preferably with copies of the relevant agreements.

Read more

18.02.2019 NL law
Brexit and data protection: preparing for a 'no-deal'

Short Reads - As it stands, the UK will exit the European Union at midnight on 29 March 2019. Therefore, businesses within the UK, or with trade relations with the UK, would be best advised to assume that a no-deal Brexit is inevitable. The exchange of personal data  within the EU is governed by the General Data Protection Regulation (GDPR). In a no-deal Brexit, the GDPR will cease to be applicable in the UK upon its EU exit.

Read more

07.02.2019 NL law
The need for speed in mergers is no reason to ignore rights of defence

Short Reads - On 16 January 2019, the European Court of Justice clarified the procedural guarantees the European Commission needs to provide to merging parties during merger reviews. According to the Court of Justice, the General Court (GC) had rightly annulled the Commission's decision to prohibit the merger of UPS and TNT. UPS's right of defence had been infringed because the Commission had failed to share the final version of the econometric model with UPS before adopting its prohibition decision.

Read more

07.02.2019 NL law
The ACM follows EU approach in its first pharmaceutical merger

Short Reads - The Dutch Authority for Consumers and Markets (ACM) recently reviewed its first merger between two pharmaceutical companies. In its conditional clearance of Aurobindo's acquisition of certain European Apotex assets, the ACM followed the European Commission's approach in assessing the merger's impact on competition. Companies will welcome the news that pharma mergers will be reviewed in a similar fashion, irrespective of whether the ACM or the European Commission conducts the review.

Read more

07.02.2019 EU law
Digitisation and competition law: past, present and future

Short Reads - It is nearly time for the European Commission to reveal its course of action in digitisation and competition law. Feedback from a public consultation and the recent conference on 'Shaping competition policy in the era of digitisation' together with the upcoming expert panel's report on the future challenges of digitisation for competition policy are likely to shape the Commission's course of action.

Read more

Our website uses cookies: third party analytics cookies to best adapt our website to your needs & cookies to enable social media functionalities. For more information on the use of cookies, please check our Privacy and Cookie Policy. Please note that you can change your cookie opt-ins at any time via your browser settings.

Privacy – en cookieverklaring